CROSSJECT : on historical support , spike , 1st target 4.1 4.5CROSSJECT : on historical support , spike , 1st target 4.1 4.5
−0.236EUR
−8.64 MEUR
145.00 KEUR
22.04 M
About CROSSJECT
Sector
Industry
CEO
Patrick Alexandre
Website
Headquarters
Dijon
Founded
2001
ISIN
FR0011716265
FIGI
BBG00622XN66
Crossject SA manufactures and markets needle free injection system. It develops and produces generic drugs such as methotrexate, epinephrin, and sumatriptan. The company distributes its products under the Zeneo brand. Crossject was founded by Patrick Alexandre and Xavière Castano on August 8, 2001 and is headquartered in Dijon, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange CROSSJECT SA EO -,10 stocks are traded under the ticker 74C.
Yes, you can track CROSSJECT SA EO -,10 financials in yearly and quarterly reports right on TradingView.
74C net income for the last quarter is −4.08 M EUR, while the quarter before that showed −4.56 M EUR of net income which accounts for 10.65% change. Track more CROSSJECT SA EO -,10 financial stats to get the full picture.
No, 74C doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 74C shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CROSSJECT SA EO -,10 stock right from TradingView charts — choose your broker and connect to your account.
We've gathered analysts' opinions on CROSSJECT SA EO -,10 future price: according to them, 74C price has a max estimate of 5.00 EUR and a min estimate of 4.40 EUR. Watch 74C chart and read a more detailed CROSSJECT SA EO -,10 stock forecast: see what analysts think of CROSSJECT SA EO -,10 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CROSSJECT SA EO -,10 EBITDA is −10.00 M EUR, and current EBITDA margin is −6.94 K%. See more stats in CROSSJECT SA EO -,10 financial statements.